Respiratory Syncytial Virus InfectionsPhase 3NCT00129766
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
A Phase 3 study testing motavizumab (MEDI-524) and palivizumab in people with Respiratory Syncytial Virus Infections, run by MedImmune LLC at 344 sites in 24 countries.
Trial summary
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. Read more about this study
- Who is it for?
- Ages Up to 24 months
- Conditions the study is for
- Respiratory Syncytial Virus Infections
- What is being tested?
- motavizumab (MEDI-524) and palivizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6,635 participants
- Where
- 344 sitesin 24 countries
- Study dates
- Nov 2004to May 2006
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 24 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- 24 months of age or younger at randomization (child must be randomized on or before his/her 24-month birthday) with a diagnosis of chronic lung disease (CLD) of prematurity requiring medical intervention/management (i.e., supplemental oxygen, bronchodilators, or diuretics) within 6 months before randomization
- OR:
- 35 weeks gestational age or less at birth and 6 months of age or younger at randomization (children were to be randomized on or before his/her 6-month birthday)
Who cannot join
- Hospitalization at the time of randomization (unless discharge was anticipated within 10 days)
- Mechanical ventilation or other mechanical support (including continuous positive airways pressure [CPAP])
- Life expectancy < 6 months
- Active RSV infection (a child with signs/symptoms of respiratory infection must have had negative RSV testing)
- Known renal impairment
- Known hepatic dysfunction
Show all 15Show fewer
- Chronic seizure or evolving or unstable neurologic disorder
- Congenital heart disease [CHD] (children with uncomplicated CHD [e.g., patent ductus arterious (PDA), small septal defect] and children with complicated CHD that were currently anatomically and hemodynamically normal could be enrolled)
- Known immunodeficiency
- Mother with HIV infection (unless the child has been proven to be not infected)
- Known allergy to Ig products
- Receipt of palivizumab, RSV-IGIV, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization
- Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)
- Previous receipt of RSV vaccines
- Participation in other investigational drug product studies
Trial locations and contacts
344 sites in 24 countries.
344 sites in 24 countries
United States120 sites
Children's Hospital Medical Center Of Akron
Akron, Ohio, 44308
Albany Medical Center
Albany, New York, 12208
Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
University of Michigan Mott Children's Hospital
Ann Arbor, Michigan, 48109
Emory University School Of Medicine
Atlanta, Georgia, 30322
Georgia Pediatric Pulmonology Associates
Atlanta, Georgia, 30342
The Medical College Of Georgia
Augusta, Georgia, 30912
University Of Maryland School of Medicine
Baltimore, Maryland, 21201
Louisiana State University MidCity Clinic
Baton Rouge, Louisiana, 70806
Central Arkansas Pediatric Clinic, PA
Benton, Arkansas, 72015
St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
University Of Alabama At Birmingham
Birmingham, Alabama, 35233
Beehly Medical Park Women's and Children's Pav.
Boardman, Ohio, 44512
Tufts-New England Medical Center
Boston, Massachusetts, 02111
Boston Medical Center
Boston, Massachusetts, 02118
The Brooklyn Hospital Center
Brooklyn, New York, 11201
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Women & Children's Hospital
Buffalo, New York, 14222
University of North Carolina-School of Medicine
Chapel Hill, North Carolina, 27516
MUSC
Charleston, South Carolina, 29425
Carolinas Medical Center
Charlotte, North Carolina, 28203
University of Virginia Hospital
Charlottesville, Virginia, 22908
University of Illinois at Chicago
Chicago, Illinois, 60612
Children's Memorial Hospital
Chicago, Illinois, 60614
University of Cincinnati Col. of Med.
Cincinnati, Ohio, 45267
Metro Health Medical Center
Cleveland, Ohio, 44109
Pediatric Clinical Trials International, Inc.
Columbus, Ohio, 43205
Advocate Hope Children's Hospital
Cook, Illinois, 60453
Driscoll Children's Hospital
Corpus Christi, Texas, 78411
Baylor University Medical Center
Dallas, Texas, 75246
Univ. Of Texas Southwestern Medical Center
Dallas, Texas, 75390
Geisinger Medical Center- JW Children's Hospital
Danville, Pennsylvania, 17822
Children's Medical Center
Dayton, Ohio, 45404
Children's Hospital
Denver, Colorado, 80218
Children's Hospital Of Michigan
Detroit, Michigan, 48201
St. John Hospital & Medical Center
Detroit, Michigan, 48236
St. Mary's Duluth Clinic
Duluth, Minnesota, 55805
Duke University Medical Center
Durham, North Carolina, 27710
Shands Hospital At The University Of Florida
Gainesville, Florida, 32610
DeVos Children's Hospital
Grand Rapids, Michigan, 49503
East Carolina University School of Medicine
Greenville, North Carolina, 27858
Connecticut Children's Medical Center
Hartford, Connecticut, 06106
Kapiolani Medical Center for Woman and Children
Honolulu, Hawaii, 96826
Texas Children's Hospital
Houston, Texas, 77030
University Of Texas Houston Medical School
Houston, Texas, 77030
University Physicians
Huntington, West Virginia, 25701
James Whitcomb Riley Hospital for Children
Indianapolis, Indiana, 46202
The Nemours Children's Clinic
Jacksonville, Florida, 32207
The Children's Clinic Of Jonesboro, P.A.
Jonesboro, Arkansas, 72401
Children's Mercy Hospital
Kansas City, Missouri, 64108
Research Medical Center
Kansas City, Missouri, 64132
Children's Lung Specialist, Ltd
Las Vegas, Nevada, 89107
Dartmouth Medical School
Lebanon, New Hampshire, 03756
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, 72202
Arkansas Pediatric Clinic
Little Rock, Arkansas, 72205
Little Rock Children's Clinic, PA
Little Rock, Arkansas, 72205
Saint Barnabas Medical Center
Livingston, New Jersey, 07039
Miller Children's Hospital
Long Beach, California, 90806
Kaiser Permanente Los Angeles
Los Angeles, California, 90027
University of Louisville
Louisville, Kentucky, 40202
Texas Tech Health Sciences Center
Lubbock, Texas, 79415
Tod Children's Hospital
Mahaning, Ohio, 44501
Marshfield Clinic
Marshfield, Wisconsin, 54449
Lebonheur Children's Medical Center
Memphis, Tennessee, 38103
University Of Miami Medical Center
Miami, Florida, 33136
St. Joseph's Hospital
Milwaukee, Wisconsin, 53210
Winthrop University Hospital
Mineola, New York, 11501
West Virginia University
Morgantown, West Virginia, 26506
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
Schneider Children's Hospital
New Hyde Park, New York, 11040
Tulane Hospital for Children
New Orleans, Louisiana, 70112
New Jersey Medical School
Newark, New Jersey, 07103
Children's Hospital of Oakland
Oakland, California, 94609
Kaiser Permanente Health Care Plan
Oakland, California, 94611
Children's Hospital Of Oklahoma
Oklahoma City, Oklahoma, 73104-5066
University of Nebraska Medical Center Pediatric
Omaha, Nebraska, 68198
Children's Hospital of Orange County
Orange, California, 92868
Nemours Children's Clinic Biomedical Research
Orlando, Florida, 32801
Lutheran General Children's Hospital
Park Ridge, Illinois, 60068
The Children's Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104
Jefferson-duPont Children's Health Program
Philadelphia, Pennsylvania, 19107
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107
Maricopa Medical Center
Phoenix, Arizona, 85008
Alabama Neonatal Medicine OC
Pike Road, Alabama, 35233
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213
Oregon Health Sciences University
Portland, Oregon, 97239
The Children's Medical Group
Poughkeepsie, New York, 12603
Rhode Island Hospital
Providence, Rhode Island, 02903
Raleigh Pediatric Associates
Raleigh, North Carolina, 27615
VCU Medical Center
Richmond, Virginia, 23298
University Of Rochester Medical Center
Rochester, New York, 14642
Children's Healthcare D.B.A. Hospitals & Clinics
Saint Paul, Minnesota, 55102
Primary Children's Medical Center
Salt Lake City, Utah, 85113
University Of Texas Health Science Center
San Antonio, Texas, 78229
University of California
San Diego, California, 92103
Children's Hospital San Diego
San Diego, California, 92123
California Pacific Medical Center
San Francisco, California, 94115
Santa Clara Valley Medical Center
San Jose, California, 95728
Sioux Valley Hospital University of South Dakota Medical Center
Sioux Falls, South Dakota, 57117
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Baystate Medical Center
Springfield, Massachusetts, 01199
Pediatric Pulmonology, LLC
Stamford, Connecticut, 06920
University Hospital State University of New York at Stony Brook Department of Pediatrics
Stony Brook, New York, 11794
Crouse Hospital NICU
Syracuse, New York, 13210
SUNY Upstate Medical University
Syracuse, New York, 13210
Univ. S. Florida Pediatrics Ambulatory Care Center
Tampa, Florida, 33606
Scott & White Memorial Hospital
Temple, Texas, 76508
Bronx-Lebanon Hospital Center
The Bronx, New York, 10457
Jacobi Medical Center
The Bronx, New York, 10461
Montefiore Medical Center
The Bronx, New York, 10467
Toledo Children's Hospital
Toledo, Ohio, 43606
St. Vincent Medical Center
Toledo, Ohio, 43608
Saint Francis Hospital EOPC
Tulsa, Oklahoma, 74136
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Children's National Medical Center
Washington D.C., District of Columbia, 20010
Waukesha Memorial Hospital, Inc
Waukesha, Wisconsin, 53188
Children's Corporate Center
Wauwatosa, Wisconsin, 53226
A. I. Dupont Hospital For Children
Wilmington, Delaware, 19803
Wake Forest University School of Medicine
Winston-Salem, North Carolina, 27157
Spain25 sites
Hospital Juan Canalejo
A Coruña, 15006
Hospital Clinic y Maternistat - Barcelona
Barcelona, 08036
Hospital Sant Joan de Déu (Barcelona)
Barcelona, 08950
Hospital Reina Sofia
Córdoba, 14004
Hospital de Cruces
Cruces, 48903
Hospital Josep Trueta
Girona
Hospital Virgen de las Nieves
Granada, 18014
Hospital de Donostia (San Sebastian)
Guipuzcoa, 20014
Hospital Materno Infantil deJaén
Jaén, 23007
Hospital General de Jerez
Jerez de la Frontera, 11407
Hospital Materno Infantil de Canarias
Las Palmas de Gran Canaria
Hospital Clínico San Carlos
Madrid, 28040
Hospital La Paz- Madrid
Madrid, 28040
Hospital Severo Ochoa
Madrid, 28911
Hospital Materno Infantil/Neumología pediátrica
Málaga, 29011
Hospital Central de Asturias
Oviedo, 33006
Hospital Clinico de Salamanca
Salamanca, 37007
Hospital Universitario de Canarias
Santa Cruz de Tenerife, 38320
Hospital Clinico Universitario de Santiago
Santiago de Compostela, 15706
Hospital Maternal Virgen del Rocío
Seville, 41013
Hospital Virgen Macarena
Seville, 41071
Hospital Joan XXIII
Tarragona, 43007
Hospital Universitario La Fe Maternidad
Valencia, 46009
Hospital Clinico Universitario de Valencia
Valencia, 46010
Hospital Xeral-Cíes
Vigo, 36204
Germany17 sites
Ruhr-Uni St. Josef Hospital
Bochum, 44791
Klinikum Duisburg, Wedau Kliniken
Duisburg, 47055
Uni-Kinderklinik
Düsseldorf, 40225
Klinik fur Kinder und Jugendliche
Erlangen, 91054
Zentrum Klinische Studien/Universtatsklinikum Freiburg
Freiburg im Breisgau, 79110
Universtatsklinikum Gottingen
Göttingen, 37075
Wittenberg/Zentrum: fur Kinderheilkunde, Universitatsklinik und Poliklinik fur Kinder and Jugendmedizin
Halle, 06120
Stiftung Hannoversche
Hanover, 30173
Im Neuenheimer Feld 153
Heidelberg, 69120
Klinik und Poliklinik und Jugendiche der Universitat Leipzig
Leipzig, 04137
Universitatskinderlinik/Zentrum Fur klinische Studien
Mainz, 55101
Kinderklinik und Kinderpoliklinik
München, 80337
Stadtisches Krankenhaus Muchen-Harlaching
München, 81545
Evangelischisches Krankenhaus
Oberhausen, 46047
Klinikum Oldenberg
Oldenberg, 26133
Klinikum Rosenheim
Rosenheim, 83022
Asklepios Kinderklinik Sankt Augustin GmbH
Sankt Augustin, 53757
France16 sites
Service de Medecine Neonatale et de reanimation pediatrique
Amiens, 80054
CHU Angers
Angers, 49033
CHU de Besancon-Hopital Saint-Jacques
Besançon, 25030
CHU Bordeaux/Hopital des enfants/Unite de Neonatologie B
Bordeaux, 33076
CH Chambery
Chambéry, BP1125
CHU Dijon
Dijon, 21079
Hopital Jeanne de Flandre
Lille, 59037
CHU Nord
Marseille, 13915
CHU Montpellier/Hoptial Arnaud de Villeneuve
Montpellier, 34000
CHU de Nantes/Hospital Mere-Enfant
Nantes, 44093
CHI Poissy/St Germain en Laye
Poissy, 78300
CHU Rennes/Hopital Sud
Rennes, 35203
CHU Rouen
Rouen, 76031
CH Pierre Haute
Strasbourg, 67098
CHU Toulouse-Hopital des Enfants
Toulouse, BP 3119
Centre Pediatrique Gatien de Clocheville
Tours, 37044
Israel16 sites
HaEmek Medical Center
Afula, 18101
Barzilai Medical Center
Ashkelon, 78306
Soroka Medical Center
Beersheba, 84101
Bnei Zion Medical Center
Haifa, 31048
Rambam Medical Center
Haifa, 31096
Carmel Medical Center
Haifa, 34362
Wolfson Medical Center
Holon, 58100
Shaare Zedek Medical Center
Jerusalem, 91031
Hadassah Ein-Kerem Medical Center
Jerusalem, 91120
Sapir Medical Center
Kfar Saba, 44281
Laniado Medical Center
Netanya
Schneider Medical Center
Petah Tikva, 49100
Kaplan Medical Center
Rehovot, 76100
Sourasky Medical Center (Ichilov)
Tel Aviv, 64239
Chaim Sheba Medical Center
Tel HaShomer, 52621
Poria Medical Center
Tiberias
Italy15 sites
Presio Ospedaliero di Alta Specializzazione "G. Salesi" - Azienda Ospedaliera Universitaria - Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"
Ancona, 60123
Ospedali Riuniti di Bergamo - Azienda Ospedaliera/Unità Operativa di Patologia Neonatale
Bergamo, 24128
Azienda Ospedaliera di Bologna - Policlinico S. Orsola - Malpighi
Bologna, 40139
Ospedale Generale di Bolzano
Bolzano, 39100
Spedali Civili di Brescia
Brescia, 25123
Azienda Ospedaliera S. Croce e Carle
Cuneo, 12100
Azienda Ospedaliera Universitaria
Foggia, 71100
Azienda USL di Imola - Ospedale di Imola
Imola, 40026
Ospedale Alessandro Manzoni Lecco - Presidio dell'Azienda Ospedaliera "Ospedale di Lecco"
Lecco, 23900
Azienda Ospedaliera Universitaria Policlinico Gaetano Martino
Messina, 98100
Azienda Ospedaliera San Gerardo
Monza, 20052
Azienda Ospedaliera di Parma
Parma, 43100
Azienda Ospedaliera Universitaria Pisana - Ospedale S. Chiara
Pisa, 56100
Azienda Sanitaria Ospedaliera O.I.R.M.-S. Anna
Torino, 10126
Azienda Ospedaliera S. Maria della Misericordoa Struttura Operativa Complessa di Patologia Neonatale e terapia Intesiva Neonatale
Udine, 33100
Poland15 sites
Klinika Neonatologii AM w Białymstoku
Bialystok, 15-274
Samodzielny Publiczny Zakład Opieki Zdrowotnej Wojewódzki Szpital im. dr Jana Biziela w Bydgoszczy, Oddział Noworodków, Wcześniaków I Intensywnej Terapii Noworodka
Bydgoszcz, 85-168
Oddział Pediatrii i Kardiologii z pododdziałem Patologii Noworodka
Bydgoszcz, 85-667
Wojewódzki Szpital Specjalistyczny, Oddział Dziecięcy
Częstochowa, 42-200
Samodzielny Publiczny Szpital Kliniczny nr 1, Klinika Neonatologii
Gdansk, 80-952
Szpital Morski im. PCK, Oddział Dziecięcy
Gdynia, 81-519
Oddzial Kliniczny Kliniki Neonatologii Szpitala Uniwersyteckiego w Krakowie
Krakow, 31-501
Niepubliczny Zakład Opieki Zdrowotnej Salmed s.c.
Łęczna, 21-010
Szpital Kliniczny nr 4 im.M.Konopnickiej, Oddział Intensywnej Terapii i Anestezjologii
Lodz, 91-738
Klinika Neonatologii, Instytut Centrum Zdrowia Matki Polki
Lodz, 93-338
Dziecięcy Szpital Kliniczny im. Prof. dr hab. n. med. Antoniego Gębali w Lublinie
Lublin, 20-093
Katedra i Klinika Neonatologii AM w Poznaniu
Poznan, 60-535
II Klinika Chorób Dzieci PAM, Samodzielny Publiczny
Szczecin, 71-252
Klinika Neonatologii AM w Warszawie
Warsaw, 00-315
Klinika Niemowlęca, Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, 04-736
Canada14 sites
Alberta Children's Hospital
Calgary, T2T 5C7
Queen Elizabeth Hospital
Charlottetown, PE C1A 8T5
University Of Alberta/Stollery Children's Hospital
Edmonton, AB T6G 2J3
Dalhousie University IWK Health Centre
Halifax, B3K 6R8
Mcmaster Children's Hospital
Hamilton, L8S 4J9
McGill University Health Centre Monteal Children's Hospital
Montreal, H3H 1P3
Sainte Justine Hospital
Montreal, H3T 1C5
Children's Hospital of Eastern Ontario
Ottawa, K1H 8L1
Centre Hospitalier de L'Universite Laval
Québec, G1V 4G2
Royal University Hospital
Saskatoon, STN 0W8
Children's And Women's Hospital of BC
Vancouver, V6H 3V4
Victoria General Hospital
Victoria, V8Z 6R5
Windsor Regional Hospital
Windsor, N8W 1L9
Manitoba Institute Of Child Health University of Manitoba
Winnipeg, R3E 3P4
Czechia12 sites
Nemocnice CB
České Budějovice, 370 87
FN Hradec Kralove Detska klinika
Hradec Králové, 500 05
Nemocnice s poliklinikou v Moste
Most, 434 64
Fakultni nemocnice
Olomouc, 775 20
FNsP Ostrava
Ostrava, 708 52
FN Plzen
Plzen-Bory, 305 99
FN Plzen
Plzen-Lochotin, 304 60
Vfn 1.Lf Uk
Prague, 128 00
Fakultni Thomayerova nemocnice S poliklinkou
Prague, 140 59
Ustav pro peci o matku a dite
Prague, 143 00
FN Motol Novorozenecke oddeleni
Prague, 150 06
Batova krajska nemocnice Zlin
Zlín, 762 75
Hungary12 sites
Semmelweis Univ.
Budapest, 1083
Semmelweis University
Budapest, 1088
Schopf-Merei Agost Hospital
Budapest, 1092
Semmelweis Univ.
Budapest, 1094
DEOEC Neonatology Division
Debrecen, 4012
DEOEC, Dept. of Pediatry
Debrecen, 4012
Petz Aladar Teaching Hospital
Győr, 9023
Borsod-Abaúj-Zemplén Megyei Önkormányzat Kórháza
Miskolc, 3501
Josa Andras Hospital
Nyíregyháza, 4400
University of Pecs
Pécs, 7623
Univ. of Pecs
Pécs, 7624
Csolnoky Ferenc Hospital
Veszprém, 8200
United Kingdom11 sites
Birmingham Heartlands Hospital
Birmingham, B9 5SS
Dumfries and Galloway Royal Infirmary
Dumfries, DG1 4AP
Children's Respiratory Medicine Division of Maternal and Child Health Sciences Ninewells Hospital
Dundee, DD1 9SY
Medway Maritime Hospital
Gillingham Kent, ME7 5NY
Princess Anne Hospital
Hants, SO16 5YA
Claredon Wing, Leeds General Infirmary
Leeds, LS2 9NS
St James' University Hospital
Leeds, LS9 7TF
James Cook University Hospital
Middlesbrough, TS4 3BW
Queen's Medical Centre Nottingham University Hospital
Nottingham, NG7 2UH
Sheffield Children's Hospital
Sheffield, S10 2TH
Royal Hampshire County Hospital
Winchester, SO22 5DG
Australia10 sites
The Canberra Hospital
Garran, Australian Capital Territory, 2605
Royal Children's Hospital (Brisbane)
Herston, Queensland, 4029
Royal Hobart Hospital
Hobart, Tasmania, 7000
Peninsula Clinical Research Centre
Kippa-Ring, Queensland, 4021
John Hunter Children's Hospital
New Lambton, New South Wales, 2305
Women's and Children's Hospital
North Adelaide, 5006
Royal Children's Hospital (Melbourne)
Parkville, Victoria, 3052
Mater Mothers Hospital Raymond Terrace
South Brisbane, Queensland, 4101
Princess Margaret Children's Hospital
Subiaco, Western Australia, 6008
Westmead Hospital
Westmead, New South Wales, 2145
Bulgaria9 sites
Multifunctional Hospital for Active Treatment "Pleven"
Pleven, 5800
University Multifunctional Hospital for Active Treatment "St. George" Neonatology Clinic
Plovdiv, 4000
University Multifunctional Hospital for Active Treatment "St. George" Clinic of Pediatrics
Plovdiv, 4002
Multifunctional Hospital for Active Treatment - Plovdiv
Plovdiv, 4003
Regional Hospital of Pulmonary Diseases
Rousse, 7004
Specialized Hospital for Active Treatment of Cardio-vascular Diseases
Sofia, 1309
Specialized Hospital for Active Treatment of Obstetrics and Gynaecology"-"Maichin Dom"
Sofia, 1431
Specialized Hospital for Active Treatment of Pediatric Diseases
Sofia, 1606
Multifunctional Hospital for Active Treatment "St. Marina"
Varna, 9010
Brazil8 sites
Hospital e Maternidade Celso Pierro-Puccamp
Campinas, 13059-900
Mernidade Nossa Senhora De Fatima
Curitiba, 80010-100
Hospital De Clinicas Da UFPR
Curitiba, 80060-900
Hospital Sao Lucas da PUC-RS de Riberiao Perto da Universidade de Sao Paulo
Porto Alegre, 90610-000
Hospital Das Clinicas Da Faculdade De Medicina
Ribeirão Preto, 14048-900
Santa Casa de Misericordia de Sao Paulo
São Paulo, 01221-020
Hospital e Maternidade Santa Marina
São Paulo, 04378-500
Hospital Universitario de Universidade de Sao Paulo
São Paulo, 05508-900
Russia7 sites
Pediatric City Hospital #13
Moscow, 103001
Morozovsky Pediatric City Hospital
Moscow, 117049
St. Petersburg City Outpatient Hospital #45
Saint Petersburg, 193312
Saint-Petersburg State Pediatric Medical Academy
Saint Petersburg, 194100
St. Petersburg State Pediatric Medical Academy
Saint Petersburg, 194100
Pediatric City Hospital #1
Saint Petersburg, 198205
Smolensk State Medical Academy
Smolensk, 214018
Chile6 sites
Hospital San Jose
Independencia, 1196
Hospital Clinico de la Universidad de Chile
Independencia
Hospital Dr. Sotero Del Rio
Puente Alto
Hospital Dr. Feliz Buines Cerda
Quinta Normal
Hospital Clinico San Borja Arriaran
Santiago
Hospital Padre Hurtado
Santiago
Greece5 sites
"P&A Kyriakou" Children's hospital
Athens, 11527
Aghia Sofia Children hospital
Athens, 11527
Aristotele University of Thessaloniki, General "AXEPA" Hospital
Thessaloniki, 54636
Hippokration Hospital, University of Thessaloniki
Thessaloniki, 54642
General hospital "Papageorgiou"
Thessaloniki, 56429
Sweden5 sites
Mälarsjukhuset
Eskilstuna, 631 88
The Queen Silvia Children's Hospital
Gothenburg, 41685
Karolinska University Hospital Solna
Stockholm, 171 76
Danderyds Sjukhus
Stockholm, 182 88
Uppsala University Hospital
Uppsala, 751 85
Argentina4 sites
Hospital Peiade Interzonal General de Augodos
Buenos Aires, B1754FWE
Hospital General De Ninos Pedro De Elizalde
Buenos Aires, C1270AAN
Sanatorio Trinidad
Capital Federal, C145AIN
Hospital Materno Neonatal
Córdoba, C5000BJH
Austria4 sites
Universitatsklinik fur Kinder und Jugenheilkunde, Graz
Graz, A-8036
LandesKrankenHaus Tulln, Kinderabteilung
Tulln, A-3430
Allgemeines KrankenHaus Universitatsklinkiken Wein
Vienna, A-1090
SMZ-Ost Donauspital Wien
Vienna, A-1220
Denmark4 sites
Paediatrisk Afdeling Herning Centralsygehus
Herning, 7400
Hillerod Sygehus Helsevej 2
Hillerød, 3400
Hvidovre Hospital
Hvidovre, 2650
Sygehus Viborg
Viborg, 8800
New Zealand4 sites
Middlemore Hospital
Auckland
Dunedin Hospital
Dunedin
Waikato Hospital
Hamilton
Palmerston North Hospital
Palmerston North
Turkey (Türkiye)4 sites
Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi Neonatoloji Ünitesi
Ankara, 06100
Ankara Üniversitesi
Ankara
Ege Üniversitesi Tıp Fakültesi
Izmir, 35100
Dokuz Eylül Üniversitesi Tıp Fakültesi
Izmir, 35340
Iceland1 site
Children's hospital, Landspitali University Hospital
Reykjavik, 101
About this study
Official title: A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.
Read the detailed description
A randomized, double-blind, palivizumab-controlled, multi-center, multi-national trial conducted during 2 Northern Hemisphere RSV seasons with an intervening season in the Southern Hemisphere. Each child only participated during a single RSV season. Approximately 6,600 children at risk for serious RSV disease were to be randomized in a 1:1 ratio to receive either 15 mg/kg of palivizumab or motavizumab by IM injection every 30 days for a total of 5 doses.
- Conditions
- Respiratory Syncytial Virus Infections
- Being tested
- motavizumab (MEDI-524), palivizumab
- Keywords
- Respiratory Syncytial Virus (RSV), motavizumab, palivizumab, Synagis
- Medical subject headings
- Respiratory Syncytial Virus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
motavizumab (MEDI-524)Biological
Also called MEDI-524
Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
palivizumabBiological
Also called Synagis
Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
| Study group | Role | What they receive |
|---|---|---|
| palivizumab | Active comparator | 15 mg/kg administered intramuscularly for 5 monthly doses Receives: Biological: palivizumab |
| motavizumab (MEDI-524) | Experimental | 15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses Receives: Biological: motavizumab (MEDI-524) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of RSV Hospitalization (Includes Deaths by RSV)
RSV hospitalization was defined as 1) a respiratory hospitalization with a positive RSV test (primary), 2) a new onset of lower respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial), or 3) death demonstrated to have been caused by RSV (by autopsy or clinical history and virologic evidence).
Measured: Days 0 - 150
Number of Participants Reporting Any Adverse Events (AEs)
Number of participants reporting one or more AEs
Measured: Days 0 - 150
Number of Participants Reporting Any Related AEs
Number of participants reporting one or more AEs considered related to study drug by the investigator
Measured: Days 0 - 150
Number of Participants Reporting Any Serious Adverse Events (SAEs)
Number of participants reporting one or more SAEs
Measured: Days 0 - 150
Number of Participants Reporting Any Related SAEs
Number of participants reporting one or more SAEs considered related to study drug by the investigator
Measured: Days 0 - 150
Number of Participants Reporting AEs by Highest Severity Grade
Adverse events events were graded by severity; Level 1, 2, 3, or 4
Measured: Days 0 - 150
Number of Participants Who Discontinued Study Drug Due to AEs
Measured: Days 0 - 150
Number of Participants Who Died
Measured: Days 0 - 150
Number of Participants Reporting Changes in Vital Signs From Baseline
Vital signs that were in a higher toxicity grade than observed at baseline were to be recorded as AEs
Measured: Days 0 - 150
Secondary outcomes (11)
The Incidence of Outpatient Medically-attended Lower Respiratory Illness (LRI)
LRI was defined as an event of bronchiolitis or pneumonia or the occurance of a lower tract infectious illness as determined by the PI based on medical history, signs, and symptoms.
Measured: Day 0 - 150
The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups
The RSV-specific LRI was defined as an outpatient medically-attended LRI associated with a positive RSV test and was not inclusive of events that required hospitalization.
Measured: Days 0 - 150
The Incidence of Medically-attended Otitis Media (OM) Infections
Otitis media (OM) was to be recorded as the diagnosis if the following terms were used by the medical care provider: acute OM, acute tympanic membrane (TM) perforation, bulging TM, red TM with fever, OM with effusion, or middle ear effusion. A new episode was defined as a physician-diagnosed OM in either ear after a normal middle ear exam of the ear in question or an episode of acute OM greater than or equal to 21 days after resolution of the previous episode. A diagnosis of persistent middle ear effusion was not to be recorded as a new OM event.
Measured: Days 0 - 150
The Frequency of Prescribed Antibiotics for Medically-attended LRI
The average number of presciptions per event per subject was summarized for each treatment group.
Measured: Days 0 - 150
The Frequency of Prescribed Antibiotics for Medically-attended OM Infections
The average number of presciptions per event per subject was summarized for each treatment group.
Measured: Days 0 - 150
The Number of Participants With Anti-motavizumab Antibodies
Detection of anti-motavizumab antibodies was defined as a titer with a dilution value equal to or greater than 1:10.
Measured: Day 0 - 120
The Serum Concentrations of Motavizumab at Day 0
Mean serum concentrations of motavizumab at Day 0
Measured: Day 0
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 1
Mean serum concentrations of motavizumab at 30 days post Dose 1
Measured: 30 days post Dose 1
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 2
Mean serum concentrations of motavizumab at 30 days post Dose 2
Measured: 30 days post Dose 2
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 3
Mean serum concentrations of motavizumab at 30 days post Dose 3
Measured: 30 days post Dose 3
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 4
Mean serum concentrations of motavizumab at 30 days post Dose 4
Measured: 30 days post Dose 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2005 (estimated)
- Study startNov 2004
- Primary completionMay 2006
- Study completionMay 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory Syncytial Virus InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 6,635 participants (actual)
Sponsor and investigators
- Lead sponsor
- MedImmune LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- M Pamela Griffin, MD, Study director, MedImmune LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00129766
- Sponsor's protocol ID
- MI-CP110
- Status last verified
- Jun 2013
- First submitted
- 10 Aug 2005
- Last updated
- 28 Aug 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Carbonell-Estrany X, Simoes EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.
PubMed 20008423
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
- ClinicalTrials.gov ID
- NCT00129766
- Acronym / sponsor ID
- MI-CP110
- Conditions
- Respiratory Syncytial Virus Infections
- Keywords
- Respiratory Syncytial Virus (RSV), motavizumab, palivizumab, Synagis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6,635 participants (actual)
- Lead sponsor
- MedImmune LLCIndustry (pharma, biotech, devices)
- Study start
- Nov 2004
- Primary completion
- May 2006 (actual)
- Study completion
- May 2006 (actual)
- First posted
- 12 Aug 2005 (estimated)
- Results
- Posted 28 Aug 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.
Detailed description
A randomized, double-blind, palivizumab-controlled, multi-center, multi-national trial conducted during 2 Northern Hemisphere RSV seasons with an intervening season in the Southern Hemisphere. Each child only participated during a single RSV season. Approximately 6,600 children at risk for serious RSV disease were to be randomized in a 1:1 ratio to receive either 15 mg/kg of palivizumab or motavizumab by IM injection every 30 days for a total of 5 doses.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| palivizumab | Active comparator | Biological: palivizumab15 mg/kg administered intramuscularly for 5 monthly doses |
| motavizumab (MEDI-524) | Experimental | Biological: motavizumab (MEDI-524)15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses |
Who may qualify
- Ages
- Up to 24 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- 24 months of age or younger at randomization (child must be randomized on or before his/her 24-month birthday) with a diagnosis of chronic lung disease (CLD) of prematurity requiring medical intervention/management (i.e., supplemental oxygen, bronchodilators, or diuretics) within 6 months before randomization
- 35 weeks gestational age or less at birth and 6 months of age or younger at randomization (children were to be randomized on or before his/her 6-month birthday)
Key exclusion criteria (15 listed)
- Hospitalization at the time of randomization (unless discharge was anticipated within 10 days)
- Mechanical ventilation or other mechanical support (including continuous positive airways pressure [CPAP])
- Life expectancy < 6 months
- Active RSV infection (a child with signs/symptoms of respiratory infection must have had negative RSV testing)
- Known renal impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| motavizumab (MEDI-524)Also: MEDI-524Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | Biological | motavizumab (MEDI-524) |
| palivizumabAlso: SynagisPalivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | Biological | palivizumab |
Primary outcome
Incidence of RSV Hospitalization (Includes Deaths by RSV)
Time frame: Days 0 - 150
RSV hospitalization was defined as 1) a respiratory hospitalization with a positive RSV test (primary), 2) a new onset of lower respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial), or 3) death demonstrated to have been caused by RSV (by autopsy or clinical history and virologic evidence).
Number of Participants Reporting Any Adverse Events (AEs)
Time frame: Days 0 - 150
Number of participants reporting one or more AEs
Number of Participants Reporting Any Related AEs
Time frame: Days 0 - 150
Number of participants reporting one or more AEs considered related to study drug by the investigator
Number of Participants Reporting Any Serious Adverse Events (SAEs)
Time frame: Days 0 - 150
Number of participants reporting one or more SAEs
Number of Participants Reporting Any Related SAEs
Time frame: Days 0 - 150
Number of participants reporting one or more SAEs considered related to study drug by the investigator
Number of Participants Reporting AEs by Highest Severity Grade
Time frame: Days 0 - 150
Adverse events events were graded by severity; Level 1, 2, 3, or 4
Number of Participants Who Discontinued Study Drug Due to AEs
Time frame: Days 0 - 150
Number of Participants Who Died
Time frame: Days 0 - 150
Number of Participants Reporting Changes in Vital Signs From Baseline
Time frame: Days 0 - 150
Vital signs that were in a higher toxicity grade than observed at baseline were to be recorded as AEs
11 secondary outcomes
The Incidence of Outpatient Medically-attended Lower Respiratory Illness (LRI)
Time frame: Day 0 - 150
The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups
Time frame: Days 0 - 150
The Incidence of Medically-attended Otitis Media (OM) Infections
Time frame: Days 0 - 150
The Frequency of Prescribed Antibiotics for Medically-attended LRI
Time frame: Days 0 - 150
The Frequency of Prescribed Antibiotics for Medically-attended OM Infections
Time frame: Days 0 - 150
The Number of Participants With Anti-motavizumab Antibodies
Time frame: Day 0 - 120
The Serum Concentrations of Motavizumab at Day 0
Time frame: Day 0
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 1
Time frame: 30 days post Dose 1
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 2
Time frame: 30 days post Dose 2
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 3
Time frame: 30 days post Dose 3
The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 4
Time frame: 30 days post Dose 4
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 20008423Carbonell-Estrany X, Simoes EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.
Related trials for Respiratory Syncytial Virus Infections
RecruitingPhase 3
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Respiratory Syncytial Virus (RSV)
Active, not recruitingPhase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
Active, not recruitingPhase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Respiratory Syncytial Virus (RSV), Infectious Disease
RecruitingPhase 2
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
Respiratory Syncytial Virus (RSV)
RecruitingObservational study
TARSILA Real-World Evidence Study
Respiratory Syncytial Virus (RSV), Maternal Immunization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
M Pamela Griffin, MD study director
MedImmune LLC
344 sites in 24 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing motavizumab (MEDI-524) and palivizumab in people with Respiratory Syncytial Virus Infections, run by MedImmune LLC at 344 sites in 24 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 344 sites in United States, Spain, Germany, France, Israel and 19 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Aug 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of RSV Hospitalization (Includes Deaths by RSV) (time frame: Days 0 - 150). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00129766, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2013.